These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Transdermal oxybutynin: a new treatment for overactive bladder. Davila GW Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930 [TBL] [Abstract][Full Text] [Related]
23. The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin. Newman DK Director; 2008; 16(1):22-5. PubMed ID: 19343871 [TBL] [Abstract][Full Text] [Related]
24. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration. Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421 [TBL] [Abstract][Full Text] [Related]
25. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474 [TBL] [Abstract][Full Text] [Related]
27. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Wang AC; Chih SY; Chen MC Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893 [TBL] [Abstract][Full Text] [Related]
28. The evolution of transdermal therapy for overactive bladder. Sand PK Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479 [TBL] [Abstract][Full Text] [Related]
29. Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14. Cornel EB Eur Urol; 2007 Jul; 52(1):286-7; author reply 287. PubMed ID: 17434252 [No Abstract] [Full Text] [Related]
30. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity. Asimakopoulos AD; Cerruto MA; Del Popolo G; La Martina M; Artibani W; Carone R; Finazzi-Agrò E Urol Int; 2012; 89(3):259-69. PubMed ID: 22777274 [TBL] [Abstract][Full Text] [Related]
31. Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study. Yoo DS; Han JY; Lee KS; Choo MS Int J Clin Pract; 2012 Feb; 66(2):132-8. PubMed ID: 22188444 [TBL] [Abstract][Full Text] [Related]
32. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678 [TBL] [Abstract][Full Text] [Related]
33. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833 [TBL] [Abstract][Full Text] [Related]
35. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Ko Y; Malone DC; Armstrong EP Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433 [TBL] [Abstract][Full Text] [Related]
36. [Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.]. Vozmediano-Chicharro R; Blasco Hernández P; Madurga-Patuel B Arch Esp Urol; 2017 Jul; 70(6):561-569. PubMed ID: 28678009 [TBL] [Abstract][Full Text] [Related]
37. [Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.]. Merino Salas S Arch Esp Urol; 2018 Jun; 71(5):502-505. PubMed ID: 29889041 [TBL] [Abstract][Full Text] [Related]
38. Fesoterodine: a new agent for treating overactive bladder. Ellsworth P; Berriman SJ; Brodsky M Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800 [TBL] [Abstract][Full Text] [Related]